Drug‐induced hemolytic anemia due to ceftriaxone in a patient with recently identified alloantibodies: A diagnostic challenge
Transfusion · 2026-07 · 66 (7) · 1444-1448
DOI: 10.1111/trf.70222 ↗Kurz gefasst
Fallbericht in der Zeitschrift Transfusion, online erschienen am 10.04.2026. Verfasst von Kavya Balusu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Rochester General Hospital, Rochester, New York, USA. Hauptthemen laut MEDLINE: Isoantibodies, Anemia, Hemolytic, Ceftriaxone, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Drug‐induced immune hemolytic anemia (DIIHA) is a rare but potentially life‐threatening condition resulting from destruction of red blood cells (RBCs) following drug exposure. Although the precise incidence is difficult to ascertain because of under‐diagnosis and under‐reporting, estimates suggest an annual incidence of 1 in 1 million. This may be because often only patients with dramatic or severe hemolysis typically undergo comprehensive immunohematologic evaluation, including diagnostic drug testing. In patients receiving blood transfusions, making a diagnosis can be even more challenging as hemolysis may be complicated by concurrent alloimmunization. Case Report We present the case of a 51‐year‐old female with recently identified anti‐E and anti‐M alloantibodies who developed severe hemolytic anemia 3 days after blood transfusion, ultimately leading to multi‐organ failure and death. Although initially suspected to be due to a delayed hemolytic transfusion reaction, further immunohematology testing confirmed ceftriaxone‐induced immune hemolytic anemia.
Conclusion
This case highlights how DIIHA can be masquerading as a delayed hemolytic transfusion reaction, underscoring the importance of considering DIIHA as a differential diagnosis, especially in patients receiving commonly implicated drugs, so that they can be promptly discontinued to avoid adverse outcomes. Confirmatory testing can be done and is usually available at an immunohematology reference laboratory.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Rochester General Hospital, Rochester, New York, USA.
- Department of Hematology/Oncology, Rochester General Hospital, Rochester, New York, USA.
- Department of Transfusion Medicine, Rochester General Hospital, Rochester, New York, USA.
- Immunohematology Reference Laboratory, Versiti Blood Center of Wisconsin, Milwaukee, Wisconsin, USA.
ORCID-Profile: Kavya Balusu
Zitieren
APA
Balusu, K., Ehsanullah, S. U., Olejniczak, J., Bensing, K., Pugh, T., Puca, K., & Choate, J. (2026). Drug‐induced hemolytic anemia due to ceftriaxone in a patient with recently identified alloantibodies: A diagnostic challenge. Transfusion, 66(7), 1444-1448. https://doi.org/10.1111/trf.70222
Vancouver
Balusu K, Ehsanullah SU, Olejniczak J, Bensing K, Pugh T, Puca K, et al. Drug‐induced hemolytic anemia due to ceftriaxone in a patient with recently identified alloantibodies: A diagnostic challenge. Transfusion. 2026;66(7):1444-1448. doi:10.1111/trf.70222
BibTeX
@article{Balusu2026,
author = {Balusu, Kavya and Ehsanullah, Syed-Usman and Olejniczak, Jennifer and Bensing, Kathleen and Pugh, Tina and Puca, Kathleen and Choate, Jacquelyn},
title = {Drug‐induced hemolytic anemia due to ceftriaxone in a patient with recently identified alloantibodies: A diagnostic challenge},
journal = {Transfusion},
year = {2026},
volume = {66},
number = {7},
pages = {1444--1448},
doi = {10.1111/trf.70222}
}
EUVIMED